Science ❯ Clinical research ❯ Oncology clinical trials ❯ Phase 3 randomized controlled trials
The agency based the approval on HER2CLIMB-05 data showing a meaningful progression-free survival gain with tucatinib while the label warns of severe hepatotoxicity and overall survival data remain immature.
